Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2019-01-11 Regulatory Filings
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Regulatory Filings Classification · 99% confidence The document is titled "Bilan semestriel du Contrat de Liquidité" (Semi-annual balance sheet of the Liquidity Contract) and reports the status of a liquidity contract (market making agreement) as of December 31, 2018, comparing it to the previous semi-annual balance (June 29, 2018). This type of regular update concerning market operations, often related to share trading or financing arrangements, does not fit neatly into the primary financial report categories (10-K, IR) or specific corporate actions (DIV, SHA, POS). Since it is a specific, periodic regulatory disclosure related to market stability/liquidity management, and it is not a standard earnings release (ER) or a comprehensive interim report (IR), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous, required disclosure, or potentially a specialized financing update (CAP). Given the context of reporting on a liquidity contract balance, RNS is the most appropriate fallback for non-standard regulatory disclosures.
2019-01-11 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it is an 'Information relative au nombre total de droits de vote et d'actions composant le capital social' (Information relating to the total number of voting rights and shares comprising the share capital) and references Article 223-16 of the AMF General Regulation. It provides a table detailing the number of shares and voting rights as of a specific date (31.12.2018). This type of mandatory disclosure regarding the total number of shares and voting rights is a standard regulatory filing in France, often related to capital structure changes or required periodic updates. Since it is a specific regulatory disclosure about share capital and voting rights, it fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Total Voting Rights Disclosure' among the provided options, and it is not a major shareholding notification (MRQ) which usually reports changes by an external entity crossing a threshold. Given the context of mandatory disclosure of capital structure information, RNS is the most appropriate fallback.
2019-01-11 French
Communicated under the obligation to provide permanent information / Other communications
AGM Information Classification · 98% confidence The document explicitly announces the convening of an 'Extraordinary Shareholders' Meeting' (EGM) scheduled for February 15, 2019. It details the agenda, which primarily concerns a €5 million equity refinancing project requiring shareholder approval. The text also mentions the publication of the prior notice in the BALO (French bulletin of mandatory legal notices) and provides details on preparatory documents and voting procedures. The core purpose of this communication is to inform shareholders about a meeting where key corporate actions (financing approval) will be decided, which strongly aligns with the purpose of a Proxy Solicitation & Information Statement (PSI) or, given the context of calling a meeting, potentially an AGM-related document, although EGM is specified. Since the document is focused on soliciting shareholder input/vote on a specific corporate action (financing) and provides details for the meeting, PSI is a strong candidate. However, the document is a press release announcing the meeting and the associated documents will be made available later. The text also mentions the prior notice published in the BALO and the availability of preparatory documents, which is characteristic of a document preceding a formal shareholder vote. Given the focus on convening a meeting to vote on a major financing event, this fits best under Proxy Solicitation & Information Statement (PSI) or potentially a general Regulatory Filing (RNS) if PSI is too specific for a press release announcing the meeting. Since the content is heavily focused on the mechanics and purpose of the upcoming vote, PSI is the most precise fit among the options for materials related to soliciting votes for a meeting, even if this specific text is the announcement of that solicitation material.
2019-01-11 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
AGM Information Classification · 98% confidence The document explicitly announces the convening of an 'assemblée générale extraordinaire des actionnaires' (Extraordinary General Meeting of Shareholders) on February 15, 2019. It details the agenda, which includes voting on a proposed capital refinancing plan. The text also mentions that the official notice ('avis préalable') was published in the BALO and that preparatory documents, including the proxy voting form ('formulaire de vote par correspondance'), will be available. This content strongly indicates materials related to soliciting shareholder votes and providing necessary information for a general meeting, which aligns perfectly with the Proxy Solicitation & Information Statement (PSI) definition. While it mentions the AGM date, the primary focus is on the preparatory materials and the call for votes for this specific EGM, making PSI the most accurate fit over AGM-R (which is usually the presentation/results of the meeting itself).
2019-01-11 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document explicitly states it is providing 'Information relative au nombre total de droits de vote et d'actions composant le capital social' and references Article 223-16 of the AMF (Autorité des marchés financiers) general regulation. It presents a table detailing the total number of shares and voting rights (gross and net) as of a specific date (30.11.2018). This content directly relates to the official disclosure of voting rights and capital structure changes, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA), as it is a formal declaration regarding voting rights.
2018-12-12 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 91% confidence The document is a press release dated December 10, 2018, announcing preliminary results presented at a scientific congress (EUROGIN 2018) regarding the company's HPV integration test. It discusses scientific findings, potential biomarker status, and includes standard sections like 'ABOUT GENOMIC VISION', 'CONTACTS', and 'FORWARD LOOKING STATEMENT'. This format is characteristic of an initial announcement of results or scientific progress, rather than a comprehensive financial report (10-K, IR) or a formal transcript (CT). Since it is an announcement of preliminary data/results, it fits best under the 'Earnings Release' (ER) category, which covers initial announcements of periodical results or significant operational/scientific updates, or potentially 'Regulatory Filings' (RNS) if it were purely a mandatory disclosure. Given the focus on new data and potential clinical impact, ER is the closest fit for a significant, non-financial results announcement, although it is not strictly quarterly earnings. However, looking at the definitions, none perfectly capture a scientific presentation announcement. Since it is a formal announcement of new data/progress, and not a full report, it is most closely aligned with the spirit of an 'Earnings Release' (ER) as a key periodic update, or potentially 'Regulatory Filings' (RNS) as a general announcement. Given the content is scientific/R&D progress rather than financial performance highlights, and it is a formal press release, 'Regulatory Filings' (RNS) serves as the most appropriate general category for non-standard, mandatory/material announcements that don't fit the specific financial or corporate action codes.
2018-12-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.